1 / 222
Table of contents
Notes
1. Scrap
1.1. Sympathomimetics
1.1.1. Adrenaline
1.1.2. Noradrenaline
1.1.3. Dopamine
1.1.4. Phenylephrine
1.1.5. Isoproterenol
1.1.6. Dobutamine
1.1.7. Dopexamine
1.1.8. Salbutamol
1.1.9. Ephedrine
1.1.10. Metaraminol
1.1.11. Phosphodiesterase inhibitor
1.2. Drugs affecting coagulation
1.2.1. Antiplatelet
1.3. Adrenergic antagonists
1.3.1. Prazosin
1.4. Antibiotics
1.4.2. Macrolides
3. Pharmacology
3.1. Pharmacology principles
3.1.1. Pharmacokinetics
3.1.1.1. Drug passage across cell membrane
3.1.1.2. Absorption
3.1.1.3. Distribution of drugs
3.1.1.3.1. Volume of distribution
3.1.1.3.2. Ionisation
3.1.1.3.3. Protein-binding
3.1.1.4. Clearance
3.1.1.5. Drug metabolism
3.1.1.6. Half-time and half-life
3.1.1.7. Compartment model
3.1.2. Pharmacodynamics
3.1.2.1. Stereochemistry
3.1.2.2. Mechanism of drug actions
3.1.2.2.1. Receptors
3.1.2.2.1.1. NMDA receptors
3.1.2.2.1.2. G-protein system
3.1.2.2.1.3. Receptor occupancy theory
3.1.2.3. Dose-response relationship
3.1.2.3.1. Drug response and tolerance
3.1.2.3.2. Altered drug response
3.1.3. Pharmacogenetics
3.1.3.1. Porphyria
3.1.3.2. Atypical plasma cholinesterase
3.1.3.3. Malignant hyperthermia
3.1.3.3.1. Dantrolene
3.1.4. Phases of clinical trials
3.1.5. Variability in drug response
3.2. Inhalational anaesthetic agents
3.2.4. Individual inhalational anaesthetic agents
3.2.4.1. Ideal inhaled anaesthetic agent
3.2.4.2. Halothane
3.2.4.3. Enflurane
3.2.4.4. Isoflurane
3.2.4.5. Desflurane
3.2.4.6. Sevoflurane
3.2.4.7. Nitrous oxide
3.2.4.8. Xenon
3.2.6. CO2 absorbent
3.3. IV anaesthetic agents
3.3.1. Ideal IV anaesthetic agent
3.3.2. Propofol
3.3.3. Etomidate
3.3.4. Ketamine
3.3.5. Barbiturate
3.5. Opioids
3.5.1. Neuraxial Opioids
3.5.2. Opioid receptors
3.5.3. Opioid agonists
3.5.3.1. Pharmacodynamics of opioids
3.5.3.2. Pharmacokinetics of opioids
3.5.3.3. Morphine
3.5.3.3.1. Morphine-6-glucuronide
3.5.3.4. Pethidine
3.5.3.5. Fentanyl
3.5.3.6. Sufentanil
3.5.3.7. Alfentanil
3.5.3.8. Remifentanil
3.5.3.9. Other opioid agonists
3.5.3.9.1. Codeine
3.5.3.9.2. Oxycodone
3.5.3.9.3. Methadone
3.5.3.9.4. Propoxyphene
3.5.3.9.5. Tramadol
3.5.3.10. Opioid dose conversion
3.5.5. Opioid antagonists
3.5.5.1. Naloxone
3.5.5.2. Naltrexone
3.5.5.3. Nalmefene
3.5.5.4. Methylnaltrexone
3.7. Neuromuscular blocking drugs
3.7.1. Depolarising NMBDs
3.7.1.1. Suxamethonium
3.7.2. Non-depolarising NMBDs
3.7.2.1. Long-acting nondepolarising NMBDs
3.7.2.1.1. Pancuronium
3.7.2.2. Intermediate-acting nondepolarising NMBDs
3.7.2.2.1. Atracurium
3.7.2.2.2. Cisatracurium
3.7.2.2.3. Vecuronium
3.7.2.2.4. Rocuronium
3.7.2.3. Short-acting nondepolarising NMBDs
3.7.2.3.1. Mivacurium
3.7.3. Neuromuscular blockade
3.7.4. Neuromuscular monitoring
3.8. Acetylcholine-related drugs
3.8.1. Anticholinesterase
3.8.2. Cholinergic agonists
3.8.3. Anticholinergic drugs
3.10. Pharmacology tables
4. Physiology
4.2. Neurophysiology
4.2.1. Nausea and vomiting
4.2.2. Circumventricular organs
4.2.3. Acetylcholine
4.2.3.1. Acetylcholine receptors
4.2.3.1.1. Nicotinic acetylcholine receptors
4.2.3.1.2. Muscarinic acetylcholine receptors
4.2.4. Neuromuscular junction
4.2.5. Gamma-aminobutyric acid (GABA)
4.2.5.1. GABA receptors
4.2.6. Glycine
4.3. GIT physiology
4.3.1. Stomach
4.4. Haematology
4.4.1. Haemostasis
4.4.1.1. Clot formation
4.4.1.1.1. Platelet plug formation
4.4.1.1.2. Coagulation cascade
4.4.1.1.3. Control of clot formation
4.4.1.2. Fibrinolysis
4.4.1.3. Coagulation factors
4.4.1.4. Vitamin K
4.5. Renal physiology
4.5.1. Renal clearance
4.6. Esterases
4.8. General physiology
4.8.1. Osmolality and tonicity
4.8.1.1. Colligative properties
5. Clinical measurements
5.1. Basic physics principles
5.1.1. Diffusion
6. Anatomy
6.1. Spinal anatomy
8. Others
8.3. Abbreviations